153 related articles for article (PubMed ID: 18651856)
21. Third-trimester maternal toxicity with nevirapine use in pregnancy.
Joy S; Poi M; Hughes L; Brady MT; Koletar SL; Para MF; Fan-Havard P
Obstet Gynecol; 2005 Nov; 106(5 Pt 1):1032-8. PubMed ID: 16260522
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
[TBL] [Abstract][Full Text] [Related]
23. Update on nevirapine: quest for a niche.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1997 Sep; 3(9):37-43. PubMed ID: 11364713
[TBL] [Abstract][Full Text] [Related]
24. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
25. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
Parienti JJ; Massari V; Reliquet V; Chaillot F; Le Moal G; Arvieux C; Vabret A; Verdon R;
AIDS; 2007 Oct; 21(16):2217-22. PubMed ID: 18090049
[TBL] [Abstract][Full Text] [Related]
26. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
27. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
[TBL] [Abstract][Full Text] [Related]
29. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
Han J; Wang L; Jiang Y; Zhang Q; Fang L; Yao J; Wang Q
Int J STD AIDS; 2009 Apr; 20(4):249-54. PubMed ID: 19304969
[TBL] [Abstract][Full Text] [Related]
30. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
Martínez E; Conget I; Lozano L; Casamitjana R; Gatell JM
AIDS; 1999 May; 13(7):805-10. PubMed ID: 10357379
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
Colafigli M; Di Giambenedetto S; Bracciale L; Fanti I; Prosperi M; Cauda R; De Luca A
HIV Med; 2009 Sep; 10(8):461-9. PubMed ID: 19459991
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of nevirapine-switch strategies for HIV treatment.
Cooper CL
HIV Med; 2006 Nov; 7(8):537-43. PubMed ID: 17105513
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
[TBL] [Abstract][Full Text] [Related]
34. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
35. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
36. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.
Lee CY; Chang HM; Kunin CM; Lee SS; Chen YS; Tsai HC
BMC Infect Dis; 2017 Apr; 17(1):261. PubMed ID: 28399808
[TBL] [Abstract][Full Text] [Related]
38. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
[TBL] [Abstract][Full Text] [Related]
39. The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosis-HIV-1 coinfection.
Armstrong-James D; Menon-Johansson A; Pozniak A
AIDS; 2009 Apr; 23(7):865-7. PubMed ID: 19307940
[TBL] [Abstract][Full Text] [Related]
40. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
